Skip to main content
. 2026 Oct 14;13:1927784. doi: 10.3389/fmed.2026.1927784

Table 2.

Cisplatin exposure table.

Renal status/timing n % Cumulative cisplatin exposure
No AKD; completed 3 cycles 1,458 100% of non-AKD 225 mg/m2
AKI/AKD after cycle 1 166 28.9% of AKD 75 mg/m2
AKI/AKD after cycle 2 278 48.3% of AKD 150 mg/m2
AKI/AKD after cycle 3 131 22.8% of AKD 225 mg/m2